mapks是一个丝氨酸/苏氨酸激酶家族，包括3个主要亚群，即erk（细胞外信号调节激酶）、p38 mapk和jnk（c-junn-末端激酶）。细胞对许多外部刺激的反应都涉及到mapk信号通路的激活。 2 mapks信号通路. mapk通路有4种主要的分支路线：erk、p38、jnk和 erk5 。尽管在功能和 ...

Upon exposure to stressful stimuli, MAP kinases phosphorylate and activate p53, leading to p53-mediated cellular responses. Recent studies have suggested a role of p53 as an upstream activator to regulate MAPK signaling via the transcriptional activation of members of the dual specificity phosphatase family.

最近的研究表明，p53作为上游激活剂，可通过双重特异性磷酸酶家族成员的转录激活来调节mapk信号传导。 由于在大多数人类肿瘤中p53和MAPK信号通路均被改变，因此了解它们的功能相互作用可能会为癌症所特有的失调的细胞增殖和存活提供新的见解。

2021年10月22日 · Parallel outline of several physiological roles of the TGFβ/p38, mitogen-activated protein kinase (MAPK), and P13k/AKT/mTOR signaling pathways. The p38 mitogen-activated kinase can be activated following upstream cytokine stimulation of the TGFβ pathway, which can subsequently activate TP53 in normal physiological conditions.

2022年1月24日 · Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor...

tp53 被普遍认为是细胞周期命运和凋亡诱导中的关键蛋白，不出所料，它是癌症中最常被劫持的控制机制之一。最近，激酶 mkk3 成为与突变 p53 功能获得相关的不同类型实体瘤的潜在治疗靶点。

2024年8月10日 · The only ACP without MAPK activation is an aggressive case of recurrent malignant human craniopharyngioma harbouring a CTNNB1 mutation and loss of TP53. Providing support for a functional role of this TP53 mutation, we show that Trp53 loss in a murine model of ACP results in aggressive tumours and reduced mouse survival.

2020年2月3日 · Firstly, employing orthogonal approaches to confirm <12% VAF TP53 mutations, we assessed the clinical impact of TP53 clonal architecture. Whilst ≥ 12% VAF TP53 mut cases were associated with...

2018年12月1日 · In the following sections we will discuss a series of studies that describes the p38 MAPK signaling pathway, DNA damage and its response, possible role of p38 MAPK pathway in DNA damage response (DDR) in p53 mutated or compromised state, activation of p38 MAPK pathway by dysfunctional telomeres and p38 MAPK as a possible drug target.

2019年3月7日 · Results: The continued presence of the druggable MAPK pathway targets in the TP53 mutant (TP53 MUT) WM35-R and SN40R2 cells was confirmed. Trametinib and vemurafenib were tested on the paired WM35/WM35-R and SJSA-1/SN40R2 cells and similar growth inhibitory effects on the paired cell lines was observed.